Personalizing
Cancer Treatment for Everyone

PRESS RELEASES

Philips HealthWorks Startup Program
Massive Bio and Philips Journey, Marching to Equalize Access in Healthcare by Combining Best Minds

2018 has been a revolutionary year for Massive Bio and clearly acceptance by Philips HealthWorks is an important milestone. 
 
Massive Bio was selected from the less than one dozen participants of an applicant base of over 200 start-ups to the Philips HealthWorks Startup Program running in Cambridge, MA focused on Precision Oncology. The program, which began in February and runs for 12 weeks, has us engaged in an intensive learning cycle with Philips, providing us with unparalleled access to experts from across their business. Massive Bio successfully graduated from the program in May 2018 and is currently exploring strategic collaboration opportunities with Philips. 

Annals of Oncology
Massive Bio Article in Annals of Oncology was ranked at to 7%

Massive Bio is at the fore-front of creating the science and technology to democratize access in precision oncology.

ASCO Aftermath
ASCO2018, The Aftermath

39,400 people registered to ASCO in 2018 with a common goal of expanding the reach of precision medicine.

Massive Bio Asco Invitation
Meet Massive Bio at ASCO 2018

Join Massive Bio executives and get your live demo at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Massive Bio will provide two types of demos: 
 
• Virtual tumor board powered by Massive Bio’s proprietary pathways and sub-specialists
 
• Clinical trial matching and eligibility screening platform powered by Artificial Intelligence (AI) and supervised by sub-specialists

VIEW ALL ARTICLES

IN THE NEWS

Cancer-fighting scanner to be unveiled

A new high technology piece cancer fighting equipment, funded by the display of some artfully decorated bras, will be unveiled to the public this week.

 

Spread of pancreatic cancer to the liver or lungs depends on plasticity of tumor cells

Pancreatic cancer often spreads, forming metastases in the liver or lungs. The prognosis is better for patients with metastases in the lungs. However, the organ that is more likely to be affected depends on the cancer cells' ability to alter their characteristics and shape - as a research team at the Technical University of Munich (TUM) has discovered

Cancer researchers suggest new treatment for rare inherited cancers

Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.

Weight loss surgery may decrease hormone-related cancer risk, study says

Researchers report that along with sharp decreases in hormone-related cancers, the risk for colorectal cancer increased by more than twofold.

 

VIEW ALL ARTICLES

PUBLISHED RESEARCH

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians.

Prognostic value of microRNAs in colorectal cancer: a meta-analysis

Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.

Harnessing the Perioperative Period to Improve Long-term Cancer Outcomes

The short perioperative period, spanning several days pre- and postsurgery, is now believed to have a nonproportionally large impact on long-term cancer outcomes (1,2). Numerous physiological responses to the newly discovered cancer and to surgical resection trigger pro-metastatic processes that can affect minimal residual disease (MRD; single tumor cells/micrometastases).

Portraits of genetic intra-tumour heterogeneity and subclonal selection across cancer types

Continued evolution in cancers gives rise to intra-tumour heterogeneity (ITH), which is a major mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. Here, we extensively characterise ITH across 2,778 cancer whole genome sequences from 36 cancer types.

VIEW ALL ARTICLES

WEBINAR

Childhood Cancer
Precision in Pediatrics: Diagnosing and Curing Childhood Cancer

Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by  Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.

If you missed the webinar, you can still watch the recording here.

 

Ask our doctors your questions about cancer
Panel of Doctors Answer Your Questions About Cancer

Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar. 

Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio. 

Cancer Treatment Doctor
Bringing state-of-the-art precision cancer care Bringing state-of-the-art precision cancer care to rural communities

Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT. 

Dr. Belisario Arango covered the following topics:

Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients? 
Where is the future of cancer care going?

VIEW ALL ARTICLES

NEWSLETTER

May 2018 Newsletter
May 2018 Newsletter - Massive Bio SYNERGY-AI Clinical Trial Program Launched Meet Massive Bio at ASCO 2018

The SYNERGY-AI registry is the first of its kind to combine artificial intelligence, genomic biomarkers and multi-variate analysis to accelerate clinical trial matching and promote access to promising cancer therapies.

VIEW ALL ARTICLES
Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us:
PLEASE FILL OUT FORM BELOW

By clicking Submit, you agree to our Terms And Conditions and have read and acknowledge our Privacy Statement.

Top